

Contents

List of Contributors *xix*

Part One: Overview of State-of-the-Art Technologies and Challenges *1*

- 1 Continuous Bioprocess Development: Methods for Control and Characterization of the Biological System *3***
Peter Neubauer and M. Nicolas Cruz-Bournazou
 - 1.1 Proposed Advantages of Continuous Bioprocessing *3*
 - 1.1.1 Introduction *3*
 - 1.2 Special Challenges for Continuous Bioprocesses *5*
 - 1.2.1 The Biological System in Continuous Biomanufacturing *5*
 - 1.2.2 Inherent Changes in the Microbial System – Problem of Evolution *6*
 - 1.2.3 Lack of Process Information *7*
 - 1.2.3.1 Models-Based Process Development and Control for Continuous Processes *8*
 - 1.2.3.2 Engineering Approach to Complex Systems *8*
 - 1.2.4 Limited Control Strategies *9*
 - 1.2.4.1 Traditional Control Strategies for Continuous Cultures *9*
 - 1.3 Changes Required to Integrate Continuous Processes in Biotech *11*
 - 1.3.1 A Better Physiological Understanding of the Organisms and Their Responses on the Reactor Environment *11*
 - 1.3.1.1 Model Complexity *11*
 - 1.3.1.2 Models *12*
 - 1.3.2 Model-Based Process Monitoring *13*
 - 1.3.3 Implementation of Model Predictive Control *14*
 - 1.3.3.1 Model-Based Control *14*
 - 1.4 Role of Iterative Process Development to Push Continuous Processes in Biotech *14*
 - 1.4.1 Methods for Development of Continuous Processes *14*
 - 1.4.1.1 Alternative: Fed-Batch as a System to Simulate Quasi Steady-State Conditions *16*

1.4.2	Mimicking Industrial Scale Conditions in the Lab: Continuous-Like Experiments	17
1.4.2.1	A Simple Model for Continuous Processes	17
1.4.2.2	Continuous-Like Fed-Batch Cultivations	18
1.4.3	Fast and Parallel Experimental Approaches with High Information Content	20
1.4.3.1	Computer-Aided Operation of Robotic Facilities	20
1.4.3.2	Model Building and Experimental Validation	21
1.5	Conclusions	22
	References	22
2	Tools Enabling Continuous and Integrated Upstream and Downstream Processes in the Manufacturing of Biologicals	31
	<i>Rimenys J. Carvalho and Leda R. Castilho</i>	
2.1	Introduction	31
2.2	Continuous Upstream Processes	32
2.2.1	Continuous Bioprocesses: With or Without Cell Recycle?	33
2.2.2	Early/Scale-Down Perfusion Development	34
2.2.3	Feeding and Operational Strategies in Perfusion Processes	35
2.2.4	Cell Retention Devices	36
2.3	Continuous Downstream Processes	41
2.3.1	Continuous Liquid Chromatography (CLC)	42
2.3.1.1	Continuous Annular Chromatography (CAC)	42
2.3.1.2	True and Simulated Moving Bed Chromatography (TMB/SMB)	43
2.3.1.3	Multicolumn Countercurrent Solvent Gradient Purification (MCSGP)	45
2.3.1.4	Periodic Countercurrent Chromatography (PCC)	47
2.3.1.5	Continuous Countercurrent Tangential Chromatography (CCTC)	50
2.3.2	Nonchromatographic Continuous Processes	51
2.3.2.1	Continuous Aqueous Two-Phase Systems	51
2.3.2.2	Continuous Protein Precipitation	52
2.3.3	Straight-Through Processes	53
2.3.4	Continuous Virus Clearance Processes	54
2.4	Integrated Continuous Processes	55
2.5	Concluding Remarks	59
	References	60
3	Engineering Challenges of Continuous Biomanufacturing Processes (CBP)	69
	<i>Holger Thiess, Steffen Zobel-Roos, Petra Gronemeyer, Reinhard Ditz, and Jochen Strube</i>	
3.1	Introduction	69
3.1.1	Continuous Manufacturing	69
3.1.2	Continuous Manufacturing of Synthetic Molecules	69
3.1.3	Continuous Manufacturing of Biologics	69
3.2	Analysis of CBP Status	71

3.3	Case Studies	74
3.4	Status and Needs for Research and Development	77
3.5	Engineering Challenges	79
3.5.1	Platform Method of QbD-Driven Process Modeling Instead of Unit Operation Oriented Platform Approaches	80
3.5.2	Data Driven Decisions	81
3.5.3	Analytics	82
3.5.4	QbD Methods	82
3.5.5	Upstream and Downstream Integration	82
3.5.6	Buffer Handling/Recycling	83
3.5.7	Process Integration of Innovative Unit Operations	84
3.5.8	ABC (Anything But or Beyond Chromatography) and AAC (Anything and Chromatography)	84
3.5.8.1	Liquid–Liquid Extraction Based on ATPE	84
3.5.8.2	Precipitation	86
3.5.8.3	Membrane Adsorbers	87
3.5.8.4	Innovative Materials Like Fibers or Matrices	88
3.5.9	Process Concepts for mAbs and Fragments	88
3.5.10	Single-Use Technology	91
3.5.11	Guided Decision for CBP	91
3.6	Conclusion and Outlook	96
	Acknowledgments	97
	References	97

Part Two: Automation and Monitoring (PAT) 107

4	Progress Toward Automated Single-Use Continuous Monoclonal Antibody Manufacturing via the Protein Refinery Operations Lab	109
	<i>David Pollard, Mark Brower, and Douglas Richardson</i>	
4.1	Introduction	109
4.2	Protein Refinery Operations Lab	111
4.2.1	Introduction	111
4.2.2	Protein Refinery Operations Lab: Design and Implementation	112
4.2.3	Protein Refinery Operations Lab: Process Analytical Technology (PAT) and Product Attribute Control (PAC) for the Transition to Real-Time Release (RTR)	117
4.2.3.1	Protein Refinery Operations Lab: Current State of PAT Technologies	118
4.3	Protein Refinery Operations Lab: Case Studies	122
4.3.1	Case Study: Perfusion	122
4.3.2	Case Study: Continuous Purification	124
4.3.3	Case Study: Proof of Concept Automated Handling of Deliberate Process Deviations	127
4.3.3.1	Perfusion Process Deviation Analysis (Bioreactor Temperature Shift)	127

- 4.3.3.2 Downstream Process Deviation Analysis
(Viral Inactivation pH) 128
- 4.4 Summary 129
- Acknowledgments 129
- References 129

Part Three: Single Use Technologies and Perfusion Technologies 131

- 5 Single-Use Bioreactors for Continuous Bioprocessing: Challenges and Outlook 133**
Nico M.G. Oosterhuis
 - 5.1 Introduction 133
 - 5.2 Single-Use Reactor Types 135
 - 5.3 Material Aspects 136
 - 5.4 Sensors 139
 - 5.5 Reactor Design 141
 - 5.5.1 Mass Transfer and Mixing Requirements for Continuous Processing 141
 - 5.6 Scale-Up Aspects 142
 - 5.7 Continuous Seed Train 145
 - 5.8 New Mixer Designs 145
 - 5.9 Future Outlook 146
 - References 147
- 6 Two Mutually Enabling Trends: Continuous Bioprocessing and Single-Use Technologies 149**
Marc Bisschops, Mark Schofield, and Julie Grace
 - 6.1 Introduction 149
 - 6.2 Single-Use Technologies 150
 - 6.2.1 History of Single-Use Technologies 150
 - 6.2.2 Single-Use Upstream Processing 151
 - 6.2.3 Single-Use Downstream Processing 151
 - 6.2.3.1 Tangential Flow Filtration 151
 - 6.2.3.2 Chromatography Steps 152
 - 6.2.4 Early Skepticism 152
 - 6.2.5 Current Trends and Future Predictions 153
 - 6.3 Continuous Bioprocessing 154
 - 6.3.1 Continuous Upstream Processing 154
 - 6.3.2 Continuous Downstream Processing 155
 - 6.3.2.1 Tangential Flow Filtration 156
 - 6.3.2.2 Continuous Chromatography 157
 - 6.3.3 Concerns for Continuous Bioprocessing 158
 - 6.4 Integrated Single-Use Continuous Bioprocessing: Case Studies 159
 - 6.4.1 Case 1: Genzyme 159
 - 6.4.2 Case 2: Merck 160

6.4.3	Case 3: Bayer Technology Services	161
6.4.4	Comparison	162
6.4.5	Challenges and Solutions	163
6.4.6	Alternative Scenarios	164
6.5	Regulatory Aspects	164
6.6	Adoption Rate of Single-Use and Continuous Bioprocessing	165
6.7	Conclusions	166
	References	167
7	Perfusion Formats and Their Specific Medium Requirements	171
	<i>Jochen B. Sieck, Christian Schild, and Jörg von Hagen</i>	
7.1	Introduction	171
7.1.1	History of Perfusion	172
7.1.2	Comeback of Perfusion	172
7.2	Characterization of Perfusion Processes	173
7.2.1	Productivity of Perfusion Processes	175
7.2.2	Cell Retention Devices	176
7.2.3	Steady-State Definition	176
7.3	Perfusion Formats	177
7.3.1	Innovative Perfusion Formats	178
7.4	Development Strategies for Perfusion Media	179
7.4.1	Cell Line-Specific Requirements	181
7.4.2	Scale-Down Models for Perfusion Processes	181
7.4.3	Scale-Down Cultivation Methods	182
7.4.4	Examples for Perfusion Scale-Down Applications	184
7.5	Process Development for Perfusion Processes	185
7.6	Case Study	185
7.6.1	Material & Methods	186
7.6.1.1	Semicontinuous Chemostat (SCC)	187
7.6.1.2	Repeated Batch (RB)	187
7.6.1.3	Semicontinuous Perfusion (SCP)	187
7.6.2	Results	187
7.6.2.1	Determination of the Starting Cell Density	187
7.6.3	Scale-Down Model Comparison	188
7.6.4	Media Screening	189
7.6.5	Bioreactor Confirmation	191
7.7	Conclusion	192
	Abbreviations	193
	References	194

Part Four: Continuous Upstream Bioprocessing 201

8	Upstream Continuous Process Development	203
	<i>Sanjeev K. Gupta</i>	
8.1	Introduction	203
8.2	Upstream Processes in Biomanufacturing	205

8.2.1	Upstream Operating Modes	206
8.2.1.1	Fed-Batch Process	206
8.2.1.2	Continuous/Perfusion Process	207
8.3	The Upstream Continuous/Perfusion Process	207
8.3.1	Upstream Process-Type Selection	209
8.3.2	Component of Continuous Upstream and Downstream Processes	209
8.3.2.1	Upstream Components: Stainless Steel and Single-Use (Su)	209
8.3.2.2	Downstream Components: Stainless Steel and Single-Use (Su)	209
8.3.3	Cell Retention Devices Used in Perfusion Process	210
8.3.3.1	Spin Filters	210
8.3.3.2	The ATF System	210
8.3.3.3	Biosep Acoustic Perfusion System	212
8.3.3.4	TFF Cell Retention Device	213
8.4	Manufacturing Scale-Up Challenges	214
8.4.1	Process Complexity and Control	214
8.4.2	Cell Line Stability	215
8.4.3	Validation	215
8.5	Single-Use Technologies: A Paradigm Change	215
8.5.1	Application of SUBs in Continuous Processing	218
8.5.2	Single-Use Continuous Bioproduction	218
8.5.3	Single-Use Perfusion Bioreactors	219
8.5.3.1	Type of Single-Use Bioreactors for Perfusion Culture	219
8.5.4	Single-Use Accessories Supporting Perfusion Culture	220
8.5.4.1	Hollow Fiber Media Exchange	220
8.5.4.2	Continuous Flow Centrifugation	220
8.5.4.3	Acoustic Wave Separation	220
8.5.4.4	Spin filters	220
8.6	FDA Supports Continuous Processing	221
8.7	Making the Switch from Batch/Fed-Batch to Continuous Processing	222
8.8	Costs and Benefits of Continuous Manufacturing	222
8.9	Costs of Adoption	223
8.10	Continuous Downstream Processing	223
8.11	Integrated Continuous Manufacturing	224
8.12	Concluding Remark	227
	Acknowledgment	228
	References	228
9	Study of Cells in the Steady-State Growth Space	233
	<i>Sten Erm, Kristo Abner, Andrus Seiman, Kaarel Adamberg, and Raivo Vilu</i>	
9.1	Introduction	233
9.1.1	On Physiological State of Cells: Steady-State Growth Space Analysis	234
9.1.2	Challenge of Comprehensive Quantitative Steady-State Growth Space Analysis (SSGSA)	236
9.1.3	Chemostat Culture – A Classical Tool for SSGSA	236

9.2	Advanced Continuous Cultivation Methods – Changestats	237
9.2.1	Accelerostat (A-stat)	237
9.2.2	Family of Changestats – A Set of Flexible Tools for Scanning Steady-State Growth Space	240
9.3	Review of the Results Obtained Using the Changestats	242
9.3.1	Acetate Overflow Metabolism in <i>E. Coli</i>	242
9.3.2	A-Stat in Study of Physiology of Yeast	243
9.3.3	Integration of A-Stat with High-Throughput Omics Methods and Modeling	243
9.3.4	A-Stat in Bioprocess Development	243
9.3.5	Deceleration-stat (De-stat)	244
9.3.6	Dilution Rate Stat (D-Stat)	244
9.3.7	Auxoaccelerostats	245
9.3.8	Adaptastat	246
9.4	SSGSA Using Parallel-Sequential Cultivations	247
9.5	Modeling in Steady-State Growth Space Analysis	248
	References	250

Part Five: Continuous Downstream Bioprocessing 259

10	Continuous Downstream Processing for Production of Biotech Therapeutics	261
	<i>Anurag S. Rathore, Nikhil Kateja, and Harshit Agarwal</i>	
10.1	Introduction	261
10.2	Continuous Manufacturing Technologies for Downstream Processing	262
10.2.1	Continuous Cell Lysis	262
10.2.2	Continuous Centrifugation	263
10.2.3	Continuous Refolding	264
10.2.4	Continuous Precipitation	267
10.2.5	Continuous Chromatography	267
10.2.6	Continuous Extraction	271
10.2.7	Continuous Filtration	272
10.3	Continuous Process Development	274
10.4	Case Studies Related to Continuous Manufacturing	276
10.5	Summary	279
	References	279
11	Evolving Needs For Viral Safety Strategies in Continuous Monoclonal Antibody Bioproduction	289
	<i>Andrew Clutterbuck, Michael A. Cunningham, Cedric Geyer, Paul Genest, Mathilde Bourguignat, and Helge Berg</i>	
11.1	Introduction	289
11.1.1	Current Regulations and Practices	293
11.1.2	Evolving Needs: Process versus Regulatory	294
11.1.3	Current Technology Landscape	295
11.2	Batch versus Continuous: Potential Impacts on Virus Safety	297

11.2.1	Raw Material Safety/Testing	299
11.2.2	Upstream and Bioreactor Safety	301
11.2.3	Downstream Virus Removal Strategies	304
11.2.3.1	Viral Reduction by Normal Flow Filtration (NFF)	304
11.2.3.2	Chemical Inactivation (Low pH or Solvent Detergent)	308
11.2.3.3	Chromatography	311
11.2.3.4	Other Techniques	312
11.3	Validation of Viral Reduction Steps in Continuous Manufacturing Processes	313
11.3.1	Protein A Capture Chromatography	314
11.3.2	Chemical Inactivation (Low pH/Solvent Detergent)	315
11.3.3	Intermediate and Polishing Chromatography	315
11.3.4	Viral Reduction Filtration	316
11.4	Conclusion	318
	References	319

Part Six: Continuous Chromatography 321

12	Multicolumn Continuous Chromatography: Understanding this Enabling Technology	323
	<i>Kathleen Muhlbachler</i>	
12.1	Introduction	323
12.2	Modes of Chromatography	326
12.3	Interaction Mechanisms Used in Chromatographic Systems	328
12.4	Batch Chromatography	330
12.5	Semicontinuous and Continuous Batch Chromatography	331
12.5.1	Single Column	331
12.5.2	Multicolumn Parallel Operation	333
12.5.3	Multicolumn Parallel and Interconnected Operation	337
12.6	Multicolumn, Countercurrent, Continuous Chromatography	340
12.6.1	Implementing Traditional SMB Technology	341
12.6.2	SMB Technology for Biomolecules	343
12.6.3	Additional Examples of SMB Purifications	349
12.7	Risk Assessment of Continuous Chromatography	353
12.8	Process Design of Continuous Capture Step	357
12.9	Conclusion	360
	References	361
13	Continuous Chromatography as a Fully Integrated Process in Continuous Biomanufacturing	369
	<i>Steffen Zobel-Roos, Holger Thiess, Petra Gronemeyer, Reinhard Ditz, and Jochen Strube</i>	
13.1	Introduction	369
13.2	Continuous Chromatography	370
13.2.1	SMB	370
13.2.2	Serial Multicolumn Continuous Chromatography	377

13.2.3	Continuous Countercurrent Multicolumn Gradient Chromatography	378
13.2.4	Integrated Countercurrent Chromatography	379
13.3	Conclusion and Outlook	386
	Symbols	388
	References	389
14	Continuous Chromatography in Biomanufacturing	393
	<i>Thomas Müller-Späth and Massimo Morbidelli</i>	
14.1	Introduction to Continuous Chromatography	393
14.2	Introduction to Manufacturing Aspects of Chromatography	396
14.3	Trade-Offs in Batch Chromatography	399
14.4	Capture Applications	400
14.4.1	Introduction	400
14.4.2	Process Principle	403
14.4.3	Application Examples	405
14.5	Polishing Applications	406
14.5.1	Introduction	406
14.5.2	MCSGP (Multicolumn Countercurrent Solvent Gradient Purification) Principle	407
14.5.3	MCSGP (Multicolumn Countercurrent Solvent Gradient Purification) Process Design	409
14.5.4	MCSGP (Multicolumn Countercurrent Solvent Gradient Purification) Case Study	412
14.6	Discovery and Development applications	414
14.7	Scale-Up of Multicolumn Countercurrent Chromatography Processes	416
14.8	Multicolumn Countercurrent Chromatography as Replacement for Batch Chromatography Unit Operations	417
14.9	Multicolumn Countercurrent Chromatography and Continuous Upstream	419
14.10	Regulatory Aspects and Control of Multicolumn Countercurrent Processes	419
	References	421
15	Single-Pass Tangential Flow Filtration (SPTFF) in Continuous Biomanufacturing	423
	<i>Andrew Clutterbuck, Paul Beckett, Renato Lorenzi, Frederic Sengler, Torsten Bisschop, and Josselyn Haas</i>	
15.1	Introduction	423
15.2	Tangential Flow Filtration in Bioproduction	426
15.2.1	Batch versus Single-Pass Tangential Flow Filtration	426
15.2.2	Membrane Type and Format for TFF Applications	426
15.2.3	Single-Pass Tangential Flow Filtration (SPTFF)	428
15.2.4	Process Design	430
15.2.5	Laboratory-Scale Process Development Example	438

- 15.2.6 Consideration on Equipment Configuration and Requirements 442
- 15.3 Validation 445
- 15.3.1 Key Validation Considerations between Batch and Continuous Processing 445
- 15.3.2 Validation of Single-Pass TFF 449
- 15.4 Conclusion 453
- References 453

Part Seven: Integration of Upstream and Downstream 457

16 Design of Integrated Continuous Processes for High-Quality Biotherapeutics 459

Fabian Steinebach, Daniel Karst, and Massimo Morbidelli

- 16.1 Introduction 459
- 16.2 Perfusion Cell Culture Development 463
- 16.2.1 Objectives and Requirements 463
- 16.2.2 Bioreactor Setup 463
- 16.2.3 Physical Bioreactor Characterization 464
- 16.3 Continuous Capture Development 466
- 16.3.1 Objectives and Requirements 466
- 16.3.2 Continuous Two-Column Capture Process 467
- 16.3.3 Process Performance 468
- 16.3.4 Process Control 469
- 16.4 Operation of the Continuous Integrated Process 470
- 16.4.1 Bioreactor Operation 470
- 16.4.2 Cell Growth 470
- 16.4.3 Monoclonal Antibody Production 471
- 16.4.4 Monoclonal Antibody Capture 472
- 16.4.5 Process Performance 473
- 16.4.6 Product Quality 474
- 16.5 Conclusion 476
- Acknowledgment 477
- References 477

17 Integration of Upstream and Downstream in Continuous Biomanufacturing 481

Petra Gronemeyer, Holger Thiess, Steffen Zobel-Roos, Reinhard Ditz, and Jochen Strube

- 17.1 Introduction 481
- 17.2 Background on Upstream Development in Continuous Manufacturing 483
- 17.3 Background on Downstream Development in Continuous mAb Manufacturing 484
- 17.4 Challenges in Process Development 485
- 17.4.1 Impact of Changing Titrers and Impurities on Cost Structures 485

17.4.2	Impurities as Critical Parameters in Process Development	487
17.4.3	Host Cell Proteins as Main Problem in Process Development	488
17.4.4	Regulatory Aspects	490
17.5	Trends and Integration Approaches	490
17.6	Methodical Approach of Integrating USP and DSP Regarding Impurity Processing	492
17.6.1	Case Study: Influence of Media Components on Impurity Production	494
17.6.2	Case Study: Influence of Harvest Operations on Impurity Production	495
17.6.3	Nonchromatographic Continuous DSP Operation	497
17.6.3.1	ATPS	498
17.6.3.2	Precipitation	499
17.6.3.3	One Step Toward a Chromatography Free Purification Process	500
17.7	Conclusion and Outlook	500
	References	501

Part Eight: Quality, Validation, and Regulatory Aspects 511

18	Quality Control and Regulatory Aspects for Continuous Biomanufacturing	513
	<i>Guillermina Forno and Eduardo Ortí</i>	
18.1	Introduction	513
18.2	FDA Support for Continuous Manufacturing	513
18.3	PAT as a Facilitator for Continuous Manufacturing Implementation	514
18.4	PAT Applications in the Pharmaceutical Industry	516
18.5	Process Validation for Continuous Manufacturing Processes	519
18.6	Regulatory Documents Related to Process Validation	520
18.7	ICH	520
18.8	FDA	520
18.9	EMA	521
18.10	ASTM	521
18.11	Special Considerations for Continuous Manufacturing Process Validation	521
18.12	Scale-Down for Continuous Bioprocessing	524
18.13	Impact of Single-Use Systems in Process Validation	526
18.14	Batch and Lot Definition	527
18.15	Conclusion	528
	References	528
19	Continuous Validation For Continuous Processing	533
	<i>Steven S. Kuwahara</i>	
19.1	Quality Management	533

19.2	Regulatory Considerations	534
19.3	Setting Specifications	534
19.4	Sequence of Events	535
19.5	Verification of Validated States	536
19.6	Choice of Test Methods	536
19.7	Types of Monitoring	536
19.8	Process Stream Analyzers	538
19.9	Validation/Qualification of Process Stream Analyzers	538
19.10	Control Charting	540
19.11	The Moving Range Chart	541
19.12	Continuous Validation	541
19.13	Choosing Other Control Charts	542
19.14	Information Awareness	542
19.15	Cost Issues	543
19.16	Revalidations	544
19.17	Management and Personnel	544
	References	545
20	Validation, Quality, and Regulatory Considerations in Continuous Biomanufacturing	549
	<i>Laura Okhio-Seaman</i>	
20.1	Introduction	549
20.1.1	What is Continuous Biomanufacturing?	549
20.1.2	Improvement in Product Quality	550
20.1.3	Manufacturing Consistency	550
20.1.4	Efficient Facility and Personnel Utilization	550
20.1.5	Reduction in Capital Expenditure and Cost	550
20.2	Quality	551
20.2.1	Other Considerations in Quality	552
20.2.1.1	Contract Manufacturing Organizations (CMO's)	552
20.2.1.2	Good Manufacturing Practices (GMP)	555
20.2.1.3	Supply Chains	555
20.2.1.4	Change Management and Control	556
20.3	Validation	557
20.3.1	Validate to Eliminate!	557
20.3.2	Test Conditions for Extractable and Leachable Analysis	560
20.3.3	Test Solutions for Extractable and Leachable Analysis	561
20.3.4	Analytical Techniques for Leachables Analysis	561
20.3.5	Description of the Model Approach	562
20.3.6	Actual Formulation Approach	563
20.4	Regulatory	564
20.4.1	Current Regulatory References	565
20.5	Conclusion	566
	Further Reading	566

Part Nine: Industry Perspectives 569

21	Evaluation of Continuous Downstream Processing: Industrial Perspective 571
	<i>Venkatesh Natarajan, John Pieracci, and Sanchayita Ghose</i>
21.1	Biogen mAb Downstream Platform Process 571
21.2	Potential Platform Process Bottlenecks Pertaining to Large Scale Manufacturing 573
21.3	Continuous Downstream Process 573
21.3.1	Multicolumn Chromatography (MCC) for Continuous Capture 575
21.3.1.1	Background 575
21.3.1.2	Process Optimization 576
21.3.1.3	Experimental Results 577
21.3.2	Continuous Viral Inactivation 578
21.3.3	Connected Chromatography Steps 580
21.3.3.1	Comparison of Current and Pool-Less Process 581
21.3.4	Continuous UF/DF Processes 582
21.4	Productivity Comparison of Batch and Continuous Downstream Process 585
	References 585
	Index 587